Trial Profile

A Phase 1, First-in-Human, Multicenter, Open-Label Study of ABSK131 to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Patients With MTAP-Deficient Advanced/Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABSK 131 (Primary)
Indications Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; First in man
Acronyms ABSK131-101
Sponsors Abbisko Therapeutics

21 Aug 2025 New trial record
23 Jul 2025 According to Abbisko Therapeutics media release, first patient has been dosed in this study.
23 Jul 2025 According to Abbisko Therapeutics media release, ABSK131 received IND clearance from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA). In December 2024, ABSK131 received IND clearance from the U.S. Food and Drug Administration.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com